Korean filler brand expands LATAM footprint with three-product clearance.
Medytox has secured regulatory approval in Colombia for three formulations of Attier hyaluronic acid fillers, marking the company's continued push into Latin American markets where HA filler demand remains robust and competition from AbbVie and Galderma is less entrenched than in North America.
Attier is Medytox's HA platform, positioned as a cross-linked, cohesive gel filler with rheological properties designed to compete on longevity and moldability against Juvéderm and Restylane. The three-product approval suggests a tiered offering—likely addressing different anatomical depths and correction volumes, from fine-line to volumization.
Medytox secures Colombian approval for three Attier HA filler formulations.
For U.S. practices, the significance is indirect but real: Medytox's international expansion validates HA filler demand outside the Allergan-Galderma duopoly and signals that Korean manufacturers are willing to invest in regulatory pathways where ROI is achievable. Colombia's approval also strengthens Medytox's negotiating position with U.S. distributors and potential MSO partners seeking non-duopoly sourcing.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
